We found that ATM mutation resulted in increased bladder cancer sensitivity to 29 drugs, including cisplatin (P < 0.05), BMS-536924, an IGF-1R inhibitor (P < 0.05), motesanib, a VEGFR inhibitor (P < 0.05), and WHI-P97, a JAK inhibitor (P < 0.05) (Figure 5). This evidence concerns the gene KDR and urinary bladder carcinoma.